Sahajanand Medical Technologies IPO Listing: Shares List At A Premium Of Over 7% On The NSE After A Strong Demand During Bidding
Add Preferred News Source
Sahajanand Medical Technologies’ shares are listed at a premium of over 7% to the issue price on the NSE. The issue was oversubscribed by 14.21 times overall and 3.04 times in the retail category.
Shares of Sahajanand Medical Technologies began trading on the domestic stock exchanges on a positive note on Friday. The stock opened at ₹371.15 apiece on the National Stock Exchange (NSE), a premium of 7.89%. On the Bombay Stock Exchange (BSE), it opened at ₹368.05 apiece, translating into a premium of 6.99%. The issue price was fixed at ₹344 per share at the upper end of the price band.
Sahajanand Medical Technologies IPO And Subscription Details
The ₹475.48-crore Sahajanand Medical Technologies initial public offering (IPO) opened for subscription on 15 October 2026 and closed on 19 October 2026. The mainboard IPO received a strong response from investors during the bidding period, with the overall subscription reaching 14.21 times. The IPO price band was fixed at ₹327–344 per share.
The qualified institutional buyer’s (QIB) quota received the maximum subscription, with the reserved portion getting subscribed by 34.70 times. The non-institutional investor (NII) category was subscribed by 14.64 times, whereas the retail portion was subscribed by 3.04 times.
The IPO comprised an offer-for-sale (OFS) of 1.38 crore equity shares. Since there was no fresh issue component, the company will not receive any proceeds from the public offering.
About Sahajanand Medical Technologies Ltd
Sahajanand Medical Technologies Limited is an India-based medical technology company with its headquarters in Surat, Gujarat. The company is engaged in the manufacturing and marketing of advanced medical devices, including coronary stents, balloons, transcatheter aortic valve implantation (TAVI) devices, occluders, renal stents and peripheral drug-coated balloons. The company sells these products under its flagship brands, including Supraflex Cruz, Cocoon, and Hydra. As of 30 June 2026, the company operated three manufacturing facilities in India and Thailand, and its products are marketed across 77 countries.
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Neha Dubey has spent 6+ years turning market chaos into something readable. At Kotak Neo, she works on IPOs and writes for the Market Ready newsletter — making sense of the markets so you don't have to.
Off the clock, she's chasing good stories, new cuisines, and the occasional impromptu singalong. A believer in small pleasures, with excellent taste for a well-timed splurge.
Right Tools, Rich Insights
